InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
-0.64%
)
Bitcoin
56,664.73
(
-0.55%
)
Post# of 252493
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ariadndndough

Send PM Follow Ignore
Followers 29
Posts 4738
Boards Moderated 0
Alias Born 12/27/2007

ariadndndough

Re: ariadndndough post# 86083

Tuesday, 11/10/2009 1:31:32 PM

Tuesday, November 10, 2009 1:31:32 PM

Post# of 252493
rkrw regarding chemgenex appears aria is better also or is this a unfair comparison

AP534 results also better than Chemgenex
ago Chemgenex also published the results of their Phase 2/3 Omacetaxine trial in pts with the T315I mutation.
http://ash.confex.com/ash/2009/webprogra...

Omacetaxine achieved major molecular response (defined as both both complete and partial cytogenetic) in 15% of pts. In a similar patient population (T315I), AP534 achieved a 33% cytogenetic response rate, more than double that of Omacetaxine. Rating :

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up